Piretanide is a loop diuretic[3] compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups. Studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics such as furosemide and bumetanide found a more suitable dose/response rate (regression line) and a more favourable sodium/potassium excretion ratio. These findings led eventually to studies in man and finally to the introduction as a saluretic and antihypertensive[4] medication in Germany, France, Italy and other countries.
Clinical data | |
---|---|
Trade names | Arelix, Eurelix, Tauliz, others |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ~90%[2] |
Protein binding | 96% |
Metabolism | not identified |
Excretion | Urine (60%), feces (40%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.054.394 |
Chemical and physical data | |
Formula | C17H18N2O5S |
Molar mass | 362.40 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
It was made in 1973, patented in 1974, and approved for medical use in 1981.[5]
Brand names include Arelix, Eurelix, Tauliz.